Skip to main content

IntriCon Acquires Emerald Medical Services

Written by Customer Service on . Posted in Mergers And Acquisitions.

Synergistic joint development and manufacturing capability expands market opportunity in surgical navigationProvides immediate access to technology platform serving new high growth medical end-markets with complex interventional catheters  Accretive transaction delivers long-term revenue growth potential and diversifies customer baseARDEN HILLS, Minn., May 19, 2020 (GLOBE NEWSWIRE) — IntriCon Corporation (NASDAQ: IIN), a designer, developer and manufacturer of miniature interventional, implantable and body-worn medical devices, today announced that it has completed the acquisition  of privately held Emerald Medical Services (EMS) Pte Ltd. The acquisition expands IntriCon’s medical coil and micro-miniature medical device engineering and manufacturing capabilities in surgical navigation and accelerates diversification into potential new end markets.Emerald Medical Services, based in Singapore, provides joint engineering and manufacturing services for complex medical devices, including catheters covering a range of applications for cardiology, peripheral vascular, neurology, radiology and pulmonology. EMS’s production capability consists of design, development, manufacturing, testing and non-sterile packaging services.Under the terms agreement to acquire EMS, the transaction consideration consists of an upfront payment of approximately $7.1 million, 80,000 shares of IntriCon common stock, and a cash earnout based on the achievement of specific sales milestones over a three-year period.“As we sought opportunities to build on our core competencies as a miniature and micro-miniature device manufacturer, Emerald Medical Services stood out as an ideal strategic complement to our business,” said Mark Gorder, president and chief executive officer of IntriCon. “We have been familiar with their high-quality design, development and manufacturing services in the complex catheter space for some time. In addition, EMS’s existing technology expands our addressable market within surgical navigation and diversifies our customer base. This transaction combines two business that are dedicated to developing and manufacturing devices that support the advancement of medical technology,” concluded Gorder.“Emerald has made significant investments in developing a portfolio of industry leading technologies and establishing a global low-cost manufacturing footprint, which makes our business synergistic with IntriCon’s strategic growth objectives,” said Steve Wiesner, chief executive officer of EMS. “We look forward to joining IntriCon at this pivotal time and to becoming a material contributor to the opportunity ahead.”IntriCon expects the acquisition to be accretive to revenue and earnings in 2020.About IntriCon Corporation
Headquartered in Arden Hills, Minn., IntriCon Corporation designs, develops and manufactures miniature interventional, implantable and body-worn medical devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better connected devices. IntriCon has facilities in the United States, Asia and Europe. The company’s common stock trades under the symbol “IIN” on the NASDAQ Global Market. For more information about IntriCon, visit www.intricon.com.About Emerald Medical ServicesFounded in 2011, Emerald Medical Services Pte Ltd (“EMS”) is a Singaporean limited liability company that provides joint development manufacturing services to medical device original equipment manufacturers (“OEMs”) with a particular focus on advanced complex catheters for cardiology, peripheral vascular, neurology, radiology and pulmonology applications.Investor Relations Contact:
Leigh Salvo
(415) 937-5404
investorrelations@intricon.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.